Products
-
- 3D BBB Models
- Organ-on-a-Chip BBB ModelsTranswell Models3D BBB Models Culture Substrate
- 3D HydrogelsCollagensAnmial BBB ModelsCell Lines for BBB Modeling
- Immortalized CellsPrimary CellsStem Cells
Human Semaphorin 3F ELISA Kit (AC2835)
Cat.#: ASET-1424
Specifications
Description Human Semaphorin 3F ELISA Kit allows for the in vitro quantitative determination of human Semaphorin 3F concentrations in serum, plasma, tissue homogenates, and other biological fluids. The kit employs the sandwich enzyme immunoassay technique. Size 96T Sample Type Serum, plasma, tissue homogenates, and other biological fluids. Reactivity Human Unit 1 kit Packaging Kit of pre-coated 96 well microplates (12 x 8 well strips) Detection Type Colorimetric Assay Type Quantitative Sensitivity 0.094 ng/ml Precision Intra-assay CV: < 8%
Inter-assay CV: < 10%Product Range 0.156-10 ng/mL Assay Time 4h 30m Storage Store the unopened kit at +4°C. Shipping Wet ice Citation Guidance If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. Related Products
Cat.# Name Assay Type Price ASET-1866 Human Arc ELISA Kit (AC3277) Quantitative inquiry ASET-1220 Human CacyBP ELISA Kit (AC2631) Quantitative inquiry ASET-1576 Mouse CHRDL1 ELISA Kit (AC2987) Quantitative inquiry ASET-2180 Rat alpha 2a Adrenergic Receptor ELISA Kit (AC3591) Quantitative inquiry ASET-1127 Rat TRPV1 ELISA Kit (AC2538) Quantitative inquiry ASET-1936 Human FADS2 ELISA Kit (AC3347) Quantitative inquiry ASET-1907 Human NOSTRIN ELISA Kit (AC3318) Quantitative inquiry ASET-1280 Human Artemin ELISA Kit (AC2691) Quantitative inquiry ASET-2250 Rat PCDHB5 ELISA Kit (AC3661) Quantitative inquiry ASET-2448 Rat Galectin 3 ELISA Kit (AC3859) Quantitative inquiry All of our products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
Quick Links0Inquiry Basket